Association between exposure to topical tacrolimus or pimecrolimus and cancers.

@article{Hui2009AssociationBE,
  title={Association between exposure to topical tacrolimus or pimecrolimus and cancers.},
  author={Rita L. Hui and William Lide and James I-Chih Chan and Joanne E. Schottinger and Monica A Yoshinaga and Mirta Millares},
  journal={The Annals of pharmacotherapy},
  year={2009},
  volume={43 12},
  pages={1956-63}
}
BACKGROUND The Food and Drug Administration has issued a public health advisory regarding cancer risk from topical calcineurin inhibitors. OBJECTIVE To compare the rates of cancer among patients with common dermatologic conditions who were exposed or not exposed to topical calcineurin inhibitors. METHODS A retrospective cohort observational study used data from an integrated healthcare delivery system on 953,064 subjects with diagnoses of atopic dermatitis or eczema between 2001 and… CONTINUE READING